Taiwan Liposome Company, Ltd. Sample Contracts

April 16th, 2018 · Common Contracts · 23 similar
Taiwan Liposome Company, Ltd.Taiwan Liposome Company, Ltd. [•] American Depositary Shares (par value NT$10 per share) Underwriting Agreement

Taiwan Liposome Company, Ltd., a Taiwanese stock corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [•] American Depositary Shares (“ADSs”), representing two shares of common stock (the “Common Stock”), nominal value NT$10 per share (the “Firm Securities”) pursuant to this underwriting agreement (the “Agreement”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional [•] ADSs representing [•] shares of Common Stock pursuant to such option, which are collectively called the “Option Securities.” The Firm Securities and, if and to the extent such option is exercised, the Option Securities, are collectively called the “Offered Securities.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Securities. To the extent

September 17th, 2018 · Common Contracts · 18 similar
Taiwan Liposome Company, Ltd.INDEMNITY AGREEMENT

THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between TAIWAN LIPOSOME COMPANY, LTD. (the “Company”), a company limited by shares under the provisions of the Company Act of the Republic of China (“ROC”), and (“Indemnitee”). This Agreement terminates any and all previous indemnification agreements entered into by and between the Company and the Indemnitee.

June 24th, 2020 · Common Contracts · 3 similar
Taiwan Liposome Company, Ltd.SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of June 18, 2020 (the “Second Amendment Date”), by and among CATHAY BANK (“Bank”) and TAIWAN LIPOSOME COMPANY, LTD., a Taiwan registered company (“Parent”), and TLC BIOPHARMACEUTICALS, INC., a Delaware corporation (“TLC,” and together with Parent, each a “Borrower” and collectively, “Borrowers”).

April 16th, 2018 · Common Contracts · 2 similar
Taiwan Liposome Company, Ltd.Contract

*** = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

April 16th, 2018 · Common Contracts · 2 similar
Taiwan Liposome Company, Ltd.Contract

*** = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

December 8th, 2017
Taiwan Liposome Company, Ltd.Contract

The English version of this document is a translation of the original version in Chinese. In the event of any discrepancies between the Chinese and English versions, the Chinese version shall prevail.

December 8th, 2017
Taiwan Liposome Company, Ltd.Premises Lease Contract

This lease contract is entered into by and between Party A and Party B through negotiation regarding the premises lease, with the following terms:

February 16th, 2018
Taiwan Liposome Company, Ltd.Contract

The English version of this document is a translation of the original version in Chinese. In the event of any discrepancies between the Chinese and English versions, the Chinese version shall prevail.

February 16th, 2018
Taiwan Liposome Company, Ltd.Premises Lease Contract

This lease contract is entered into by and between Party A and Party B through negotiation regarding the premises lease, with the following terms:

August 4th, 2021
Taiwan Liposome Company, Ltd.First Amendment to the Share Swap Agreement

This first amendment to the share swap agreement (the “Amendment”) is entered into by and between Woods Investment Company, Ltd., a company limited by shares incorporated pursuant to the laws of the Republic of China with unified business number of 90829607 (“Party A”) and Taiwan Liposome Co., Ltd., a company limited by shares incorporated pursuant to the laws of the Republic of China with unified business number of 16176150 (“Party B”, Party A and Party B are collectively referred to as “Parties” and each, a “Party”) on August 4, 2021.

April 30th, 2019
Taiwan Liposome Company, Ltd.FIRST Amendment

THIS first AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of April 25, 2019, by and between CATHAY BANK (“Bank”) and TAIWAN LIPOSOME COMPANY, LTD., a Taiwan registered company (“Parent”), and TLC BIOPHARMACEUTICALS, INC., a Delaware corporation (“TLC,” and together with Parent, each a “Borrower” and collectively, “Borrowers”).